

ARNOLD & PORTER LLP

Thomas E. Holsten  
Thomas\_Holsten@aporter.com

202.942.5085  
202.942.5999 Fax

555 Twelfth Street, NW  
Washington, DC 20004-1206

1645  
(Box 569)  
JFW

April 21, 2005

**Mail Stop Sequence**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Conf. No. 1018

Art Unit: 1645

Examiner: Sarvamangala J.N. Devi

Re: U.S. Application No. 09/445,517 filed December 6, 1999  
Title: Methods for Treating Obesity  
Applicants: Bradford J. DUFT *et al.*  
Atty. Docket: 18528.230 - 235/013 US

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (PTO):

1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
3. Sequence Listing in Computer Readable Form on floppy diskette;
4. Paper copy of Sequence Listing (13 pages);
5. Statement Regarding Sequence Submission;
6. Amendment in Response to Notice under 37 C.F.R. §§ 1.821-1.825; and
7. Return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.

Submitted herewith is a sequence listing in computer readable form on floppy diskette. The sequence listing diskette contains one file called "18528230 seq.txt" which is 14,675 bytes in size (measured in Windows XP) and was created on April 21, 2005.

---


ARNOLD & PORTER LLP

---

Commissioner for Patents  
Atty. Docket: 18528.230 - 235/013 US  
April 21, 2005  
Page 2

In the event that extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned. Applicants do not believe any additional fees are due in conjunction with this filing. However, if any fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387, referencing matter number 18528.230. A duplicate copy of this letter is enclosed.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'T.E.H.', with a long horizontal stroke extending to the left.

Thomas E. Holsten (Reg. No. 46,098)  
David R. Marsh (Reg. No. 41,408)

Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of:

Bradford J. DUFT *et al.*

Appln. No.: 09/445,517

Filed: December 6, 1999

For: Methods for Treating Obesity

Confirmation No. 1018

Art Unit: 1645

Examiner: Sarvamangala J.N. Devi

Atty. Docket: 18528.230 - 235/013 US

**Response to Notice to Comply With Requirements  
for Patent Applications Containing Nucleotide Sequence  
and/or Amino Acid Sequence Disclosures**

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed March 21, 2005, Applicants submit the following documents for appropriate action by the U.S. Patent and Trademark Office:

1. Copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Sequence listing in computer readable form (CRF) on floppy diskette;
3. Sequence listing in paper form (13 pages);
4. Amendment in Response to Notice under 37 C.F.R. §§ 1.821-1.825; and
3. Statement Regarding Sequence Submission.


A paper copy of the Sequence Listing and a computer readable form (CRF) of the sequence listing on floppy diskette, containing the file named 18528230 seq.txt, which is 14,675

bytes in size (as measured in Windows XP), and which was created on April 21, 2005, are herein incorporated by reference.

***Remarks***

The Sequence Listing is herewith being provided in computer readable form and in paper form. The Sequence Listing and the accompanying Amendment in Response to Notice under 37 C.F.R. §§ 1.821-1.825 are being provided to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. No new matter has been added.


Respectfully submitted,

A handwritten signature in black ink, appearing to be "T. E. H. D. R. M.", written over a horizontal line.

Thomas E. Holsten (Reg. No. 46,098)  
David R. Marsh (Reg. No. 41,408)

Date: April 21, 2005

ARNOLD & PORTER LLP  
Attn: IP Docketing  
555 Twelfth Street, N.W.  
Washington, D.C. 20004-1206  
(202) 942-5000 telephone  
(202) 942-5999 facsimile



Application No.: 09/445,517

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: The amino acid sequences recited in claims 41-52 and pages 15-18 of the specification are not identified by SEQ ID numbers as required.

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**